{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:31:54Z","timestamp":1777926714006,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpedhc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Health Care"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.pedhc.2025.12.020","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:09:48Z","timestamp":1768306188000},"page":"464-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Atypical Antipsychotics in Pediatric Populations"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3184-3994","authenticated-orcid":false,"given":"Beth","family":"Heuer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Whited","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pedhc.2025.12.020_bib0001","series-title":"Diagnostic and statistical manual of mental health disorders- 5th Edition Text Revision [DSM-5-TR]","year":"2022"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0045","unstructured":"ARIPiprazole (Pediatric and Neonatal Lexi-Drugs) - UpToDate\u00ae Lexidrug\u2122 (2005a). Accessed September 18, 2025."},{"issue":"9","key":"10.1016\/j.pedhc.2025.12.020_bib0002","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40263-016-0367-y","article-title":"Aripiprazole and acute extrapyramidal symptoms in children and adolescents: A meta-analysis","volume":"30","author":"Bernagie","year":"2016","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.pedhc.2025.12.020_bib0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/brainsci14121231","article-title":"Therapeutic approach to primary tic disorders and associated psychiatric comorbidities","volume":"14","author":"Berzosa-Gonzalez","year":"2024","journal-title":"Brain Sciences"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0004","series-title":"Antipsychotics: An updated primer for prescribers","author":"Bjugstad","year":"2025"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0005","series-title":"Pediatric psychopharmacology evidence: A Clinician\u2019s Guide","article-title":"Psychopharmacology for pediatric aggression","author":"Blader","year":"2024"},{"issue":"01","key":"10.1016\/j.pedhc.2025.12.020_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0008","series-title":"Data and Statistics on Children\u2019s Mental Health. Children\u2019s Mental Health","year":"2025"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0009","series-title":"Dulcan\u2019s Textbook of Child and Adolescent Psychiatry (3rd Edition)","article-title":"Antipsychotic medications","author":"Correll","year":"2022"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0010","series-title":"Medical Genetics Summaries","article-title":"Aripiprazole therapy and CYP2D6 genotype","author":"Dean","year":"2025"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0011","series-title":"Katzung's Basic and Clinical Pharmacology","article-title":"Antipsychotic agents and lithium","author":"DeBattista","year":"2023"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0013","unstructured":"Epocrates. (2025). Atypical antipsychotics. https:\/\/www.epocrates.com\/online\/results?query=atypical%20antipsychotics"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0014","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jad.2023.07.082","article-title":"Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis","volume":"339","author":"Garcia-Rodriguez","year":"2023","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0015","series-title":"StatPearls [Internet]","article-title":"Biochemistry, Cytochrome P450","author":"Gilani","year":"2023"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0016","first-page":"15","article-title":"The signaling and pharmacology of the dopamine D1 receptor","author":"Jones-Tabah","year":"2022","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"5","key":"10.1016\/j.pedhc.2025.12.020_bib0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18773\/austprescr.2019.052","article-title":"Stopping and switching antipsychotic drugs","volume":"42","author":"Keks","year":"2019","journal-title":"Australian Prescriber"},{"issue":"9","key":"10.1016\/j.pedhc.2025.12.020_bib0018","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clinthera.2022.07.011","article-title":"Pediatric off-label antipsychotic use for attention-deficit\/hyperactivity disorder","volume":"44","author":"Lee","year":"2022","journal-title":"Clinical Therapeutics"},{"issue":"10","key":"10.1016\/j.pedhc.2025.12.020_bib0019","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: A concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/j.pedhc.2025.12.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069114","article-title":"Use of second-generation antipsychotics in autism spectrum disorder: A systematic review and meta-analysis protocol","volume":"13","author":"Lopes","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0021","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1017\/S2045796021000494","article-title":"Cardiovascular and metabolic risk of antipsychotics in children and young adults: A multinational self-controlled case series study","volume":"30","author":"Man","year":"2021","journal-title":"Epidemiology in Psychiatry Sciences"},{"issue":"334","key":"10.1016\/j.pedhc.2025.12.020_bib0022","article-title":"Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis","author":"Merino","year":"2024","journal-title":"Psychiatry Residency"},{"issue":"5","key":"10.1016\/j.pedhc.2025.12.020_bib0023","article-title":"Atypical antipsychotics for autism spectrum disorder: A network meta-analysis (Protocol)","author":"Meza","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1016\/j.pedhc.2025.12.020_bib0024","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ph16040603","article-title":"Receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders","volume":"16","author":"Mlambo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0025","series-title":"Pediatric Psychopharmacology Evidence: A Clinician's Guide","article-title":"Ensuring appropriate use of psychotropic medications in pediatrics: Best practices in medication discontinuation (deprescribing)","author":"Morgan","year":"2023"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0046","unstructured":"OLANZapine (Pediatric and Neonatal Lexi-Drugs) - UpToDate\u00ae Lexidrug\u2122 (2005b). Accessed September 14, 2025."},{"issue":"3","key":"10.1016\/j.pedhc.2025.12.020_bib0026","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/futurepharmacol2030018","article-title":"The pharmacogenetics of treatment with quetiapine","volume":"2","author":"Ortega-Ruiz","year":"2022","journal-title":"Future Pharmacology"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0027","unstructured":"PharmGKB. (2023). Annotation of DPWG Guideline for risperidone and CYP2D6. https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166104943. Accessed October 15, 2025."},{"key":"10.1016\/j.pedhc.2025.12.020_bib0028","unstructured":"PharmGKB. (2025). Olanzapine. https:\/\/www.pharmgkb.org\/chemical\/PA450688\/overview. Accessed October 15, 2025."},{"issue":"2","key":"10.1016\/j.pedhc.2025.12.020_bib0029","article-title":"A systematic review of the need for guideline recommendations; Slow tapering vs. maintenance dose in long-term antipsychotic treatment: 2022","volume":"15","author":"Potla","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.pedhc.2025.12.020_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00787-020-01582-9","article-title":"Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression","volume":"31","author":"Pozzi","year":"2022","journal-title":"European child & adolescent psychiatry"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0047","unstructured":"QUEtiapine (Pediatric and Neonatal Lexi-Drugs) - UpToDate\u00ae Lexidrug\u2122 (2005c). Accessed September 16, 2025."},{"issue":"11","key":"10.1016\/j.pedhc.2025.12.020_bib0031","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.3390\/biomedicines10112818","article-title":"Antipsychotics in the management of disruptive behavior disorders in children and adolescents: An update and critical review","volume":"10","author":"Rajkumar","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0048","unstructured":"RisperiDONE (Pediatric and Neonatal Lexi-Drugs) - UpToDate\u00ae Lexidrug\u2122 (2005d). Accessed September 9, 2025."},{"issue":"2","key":"10.1016\/j.pedhc.2025.12.020_bib0033","article-title":"Efficacy of behavioural intervention, antipsychotics, and alpha agonists in the treatment of tics disorder in Tourette\u2019s Syndrome","volume":"14","author":"Rizwan","year":"2022","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.pedhc.2025.12.020_bib0036","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1007\/s10072-022-06235-0","article-title":"Tics: Neurological disorders determined by a deficit in sensorimotor gating processes","volume":"43","author":"Schilke","year":"2022","journal-title":"Neurological Sciences"},{"issue":"1","key":"10.1016\/j.pedhc.2025.12.020_bib0037","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1038\/s41598-023-33979-2","article-title":"Psychopharmacological treatment of disruptive behavior in youths: systematic review and network meta-analysis","volume":"13","author":"Seok","year":"2023","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0038","series-title":"Physiology, neurotransmitters","author":"Sheffler","year":"2023"},{"issue":"5","key":"10.1016\/j.pedhc.2025.12.020_bib0039","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5863\/1551-6776-26.5.460","article-title":"Most second-generation antipsychotic prescriptions in community practice are neither FDA-approved nor within prescribing guideline recommendations","volume":"26","author":"Singhal","year":"2021","journal-title":"The Journal of Pediatric Pharmacology and Therapeutics"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0040","unstructured":"Smith, N., Gusovsky, A., Vasudevan, V., Grego Nagel, A., Delcher, C. (2025). Disparities in the prescribing of neurologic and mental health medications in patients with autism spectrum disorder versus counterparts without ASD. Autism by the Numbers 2025 Annual Report. autismspeaks.org\/ABN"},{"issue":"6","key":"10.1016\/j.pedhc.2025.12.020_bib0041","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00213-024-06554-4","article-title":"Withdrawal syndrome after antipsychotics discontinuation: An analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022","volume":"241","author":"Storck","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0042","series-title":"Pediatric psychopharmacology evidence: A Clinician's Guide","article-title":"Introduction to the fundamentals of pediatric psychopharmacology","author":"Strange","year":"2023"},{"issue":"2","key":"10.1016\/j.pedhc.2025.12.020_bib0043","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/cap.2024.0024","article-title":"Long-acting injectable antipsychotic initiation in child and adolescent patients with psychiatric disorders","volume":"35","author":"Sun","year":"2024","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1016\/j.pedhc.2025.12.020_bib0044","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/PPA.S343211","article-title":"Antipsychotic-related stigma and the impact on treatment choices: A systematic review and framework synthesis","volume":"16","author":"Townsend","year":"2022","journal-title":"Patient Preference and Adherence"},{"issue":"5","key":"10.1016\/j.pedhc.2025.12.020_bib0049","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaac.2022.10.001","article-title":"Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders","volume":"62","author":"Walter","year":"2023","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"issue":"22","key":"10.1016\/j.pedhc.2025.12.020_bib0050","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015816","article-title":"Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine"}],"container-title":["Journal of Pediatric Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891524525004225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891524525004225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:18:24Z","timestamp":1777673904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891524525004225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0891524525004225"],"URL":"https:\/\/doi.org\/10.1016\/j.pedhc.2025.12.020","relation":{},"ISSN":["0891-5245"],"issn-type":[{"value":"0891-5245","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Atypical Antipsychotics in Pediatric Populations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Health Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pedhc.2025.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}